A gamma-Lactam Siderophore Antibiotic Effective against Multidrug-Resistant Gram-Negative Bacilli.
Goldberg, J.A., Nguyen, H., Kumar, V., Spencer, E.J., Hoyer, D., Marshall, E.K., Cmolik, A., O'Shea, M., Marshall, S.H., Hujer, A.M., Hujer, K.M., Rudin, S.D., Domitrovic, T.N., Bethel, C.R., Papp-Wallace, K.M., Logan, L.K., Perez, F., Jacobs, M.R., van Duin, D., Kreiswirth, B.M., Bonomo, R.A., Plummer, M.S., van den Akker, F.(2020) J Med Chem 63: 5990-6002
- PubMed: 32420736 
- DOI: https://doi.org/10.1021/acs.jmedchem.0c00255
- Primary Citation of Related Structures:  
6VOT - PubMed Abstract: 
Treatment of multidrug-resistant Gram-negative bacterial pathogens represents a critical clinical need. Here, we report a novel γ-lactam pyrazolidinone that targets penicillin-binding proteins (PBPs) and incorporates a siderophore moiety to facilitate uptake into the periplasm. The MIC values of γ-lactam YU253434, 1 , are reported along with the finding that 1 is resistant to hydrolysis by all four classes of β-lactamases. The druglike characteristics and mouse PK data are described along with the X-ray crystal structure of 1 binding to its target PBP3.
Organizational Affiliation: 
Research Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio 44106, United States.